scholarly journals Creditable Health Information? An Analysis of Human Papillomavirus Vaccine Messages on YouTube

2021 ◽  
pp. 8-16
Author(s):  
Angela Chia-Chen Chen ◽  
Elizabeth Reifsnider ◽  
Lihong Ou ◽  
Steven Samrock ◽  
Renuka Vemuri ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Health Information ◽  
Hpv Vaccine ◽  
Medical Center ◽  
Health Belief ◽  
Primary Vaccination ◽  
Hpv Infection ◽  
Human Papillomavirus Vaccine ◽  
Transmitted Infection ◽  
Youtube Videos

Aims: Human papillomavirus (HPV) infection is the most common sexually transmitted infection globally. Vaccination is effective in preventing HPV-associated cancers and is recommended for children at ages 11-12; however, the vaccination rate is suboptimal. Credible information about HPV vaccine in social media will help the public make effective healthcare decisions. This study analyzed YouTube videos about HPV vaccine. Study Design: Descriptive study.  Place and Duration of Study: Videos in English posted on YouTube during 2006-2020. Methodology: We used purposive sampling to select and conduct a quantitative content analysis of 151 YouTube videos that met the criteria. An instrument including video characteristics and theoretical constructs of the Health Belief Model was used to code the videos. Three researchers independently coded the data; another three verified the accuracy. The team discussed discrepancies until reaching a consensus. We conducted descriptive and inferential statistics. Results: The major source of videos were medical centers/hospitals (26%), government (22%), media (20%), and consumers (15%). About 80% of the videos were positive in tone. Information covered included vaccine knowledge (85.4%), benefits (81.5%), severity if infected (79.5%), susceptibility (60.9%), and barriers (37.7%). The primary vaccination barriers were lack of knowledge of HPV and vaccine (12.6%), worries about adverse events/safety of vaccine (14.6%) and its side effects (9.3%). Videos in neutral tone had the highest number of views, likes and dislikes. Negative tone was mostly found in videos made by consumers and media while positive tone was found in videos made by governmental agencies and medical center/hospital.   Conclusion: Despite YouTube being a popular avenue to disseminate health information and influence care, the HPV-related information on YouTube is mixed. Anecdotal health information without scientific support can mislead individuals’ decision in vaccination. Educational videos with comprehensive and accurate HPV information addressing barriers are imperative to promote vaccination and prevent HPV-related cancers.

scholarly journals An Integrative Review of the Influences on Decision-Making of Young People About Human Papillomavirus Vaccine

2018 ◽  
Vol 35 (1) ◽  
pp. 39-50
Author(s):  
Helen Sisson ◽  
Yvonne Wilkinson
Keyword(s):  
Decision Making ◽  
Human Papillomavirus ◽  
Parental Involvement ◽  
Health Care Providers ◽  
Hpv Vaccine ◽  
Hpv Infection ◽  
School Nurses ◽  
Human Papillomavirus Vaccine ◽  
Care Providers ◽  
To Receive

The human papillomavirus (HPV) vaccine is a key intervention in the prevention of HPV infection and associated cancers. This review emphasizes the importance of understanding what influences decision-making about this vaccine. Guided by the work of Whittemore and Knafl, and Pluye and Hong, we identified 25 studies, from which four prominent themes emerged: fear and risk, pain, parental involvement, and involvement of others. Fear of cervical cancer was a strong motivation to receive the vaccine, and the extent of parental involvement also had an impact on decision-making. Recommendations to receive the vaccine by health-care providers were also an important influence. School nurses are fundamental to the promotion and delivery of the HPV vaccine and should stress the significant role that it plays in the prevention of cancer. Additionally, school nurses should ensure that discussions about HPV infection and vaccine include parents where appropriate and should distinctly recommend vaccination to those eligible.

scholarly journals High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China

2021 ◽  
Vol 8 ◽  
Author(s):  
Ze-Hao Ye ◽  
Zhao-Zhen Liu ◽  
Si-Tong Cui ◽  
Zhen-Xing Chu ◽  
Yong-Jun Jiang ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Hpv Vaccine ◽  
Online Survey ◽  
Cost Effective ◽  
Hpv Infection ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Acceptability ◽  
Cross Sectional ◽  
Sex With Men

Background: Despite the insupportable burden caused by the human papillomavirus (HPV) and high vaccine acceptability, vaccination programs are not currently available for men who have sex with men (MSM). We aimed to assess HPV infection by examining the willingness for vaccination among MSM and cost-effectiveness of the Chinese 2-valent HPV vaccine.Methods: We recruited MSM in Shenyang, China between July and December 2020 to conduct anal HPV testing and an online survey regarding HPV-related knowledge and vaccine acceptability. We performed a cost-effectiveness analysis to evaluate the incremental cost-effectiveness ratios (ICERs) of the Chinese 2-valent HPV vaccine.Results: A total of 234 participants completed the online survey; of those, 203 were successfully tested for HPV. The median age was 30 years [interquartile range (IQR): 23–38 years]. Most participants had at least undergraduate education (136/234, 58.1%). The acceptability rate for the free HPV vaccine was 57.7% (135/234). The prevalence of HPV types 16 and 18 was 14.9% (18/121) and 26.8% (22/82) in the willing and unwilling to vaccinate groups, respectively (P > 0.05). The prevalence of high-risk HPV among participants aged <30 and ≥50 years was 48.6 and 38.9%, respectively. Using the Chinese per capita gross domestic product (GDP) as a threshold, the Chinese 2-valent HPV vaccine would be a “very cost-effective” strategy, with an ICER value of USD 4,411. This evidence showed that the Chinese 2-valent HPV vaccine was more cost-effective than other imported vaccines.Conclusions: Targeted strategies should be utilized in MSM with different rates of vaccine acceptability. A pilot HPV vaccination program based on the Chinese 2-valent HPV vaccine for MSM is urgently warranted to reduce the burden of HPV and anal cancer.

Review of Evidence and Recommendation for Human Papillomavirus (HPV) Vaccination of Canadian Males Over the Age of 26 Years

2020 ◽  
Vol 24 (3) ◽  
pp. 285-291 ◽  
Author(s):  
Alex Derstenfeld ◽  
Kyle Cullingham ◽  
Zhuo Cai Ran ◽  
Ivan V. Litvinov
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Older Men ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Vaccination Programs ◽  
Sexually Transmitted ◽  
Control And Prevention

Human papillomavirus (HPV) remains the most common sexually transmitted infection with a lifetime incidence of over 75%. Based on US data from the Centers for Disease Control and Prevention (CDC), 64% of invasive HPV-associated cancers are attributable to HPV 16 or 18 (65% for females; 63% males) and may be prevented by vaccination with either the quadrivalent or nonavalent HPV vaccine. Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada. Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age. There now exist compelling reasons to recommend vaccination against HPV amongst males >26 years of age. Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.

Intention of college students to receive the human papillomavirus vaccine

2016 ◽  
Vol 116 (4) ◽  
pp. 342-355 ◽  
Author(s):  
Keith Richards
Keyword(s):  
College Students ◽  
Human Papillomavirus ◽  
Information Seeking ◽  
Hpv Vaccine ◽  
Human Papillomavirus Vaccine ◽  
Transmitted Infection ◽  
Content Type ◽  
Sexually Transmitted ◽  
The Usa ◽  
To Receive

Purpose – The purpose of this paper is to better understand what influences the intentions of college students to receive the human papillomavirus (HPV) vaccine. HPV is the most common sexually transmitted infection in the USA and cancers related to HPV are on the rise. Design/methodology/approach – A 2×2 experimental design was used to predict the intentions. Messages were created that manipulated the level of severity and vulnerability to determine which would increase intentions to receive the HPV vaccine. Each of the 278 participants viewed a message that contained one severity message (high or low) and one vulnerability message (high or low). Findings – Regression was used to determine that elements of the protection motivation theory such as vulnerability and fear, along with norms, and information seeking explained a significant portion of the variance in intent to be vaccinated (R2=0.40, F(4, 268)=44.47, p < 0.001). Norms had the most influence on intention (β=0.42, p < 0.001), next was vulnerability (β=0.21, p < 0.001) then fear (β=0.16, p=0.002), and finally information seeking (β=0.10, p=0.01). Originality/value – The current college age population did not have the opportunity to be vaccinated early and the recent (2011) recommendation that males get vaccinated makes this research valuable to those designing vaccination messages. The current study shows that norms were the most influential variable in regards to increasing intent to get vaccinated. This means that if the participant believed their friends would support or endorse their intent to get vaccinated they were more likely to say they would follow through and get vaccinated. This finding should be highlighted in any future campaign.

scholarly journals Acceptability of the Human Papillomavirus Vaccine Among Urban Adolescent Males

2012 ◽  
Vol 7 (1) ◽  
pp. 27-36 ◽  
Author(s):  
Baudelio Gutierrez ◽  
Anthony Leung ◽  
Kevin Trimell Jones ◽  
Peter Smith ◽  
Randee Silverman ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Adolescent And Young Adult ◽  
Human Papillomavirus Vaccine ◽  
Adult Males ◽  
Urban Adolescent ◽  
Increased Risk ◽  
Sex With Men

The human papillomavirus (HPV) vaccine was recently approved for use in males. Certain groups, such as men who have sex with men (MSM), are at increased risk of HPV infection. The purpose of the study was to understand perceptions of HPV and the vaccine among adolescent and young adult males, both heterosexual and MSM. Seventy-six males (45 heterosexual, 31 MSM) completed a questionnaire and participated in a focus group. Overall, 42% had heard of HPV and 39% had heard of the HPV vaccine. Males had moderate to favorable attitudes toward vaccination, although intentions to vaccinate were more neutral. MSM were more knowledgeable, aware, and in control of the decision to vaccinate than heterosexual males. Increasing awareness and knowledge about HPV and the vaccine may be necessary to encourage vaccination; certain subgroups of males may be more receptive to HPV vaccination than others.

scholarly journals Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses

2019 ◽  
Vol 221 (6) ◽  
pp. 910-918 ◽  
Author(s):  
Lauri E Markowitz ◽  
Allison L Naleway ◽  
Nicola P Klein ◽  
Rayleen M Lewis ◽  
Brad Crane ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Infection ◽  
Vaccine Effectiveness ◽  
Human Papillomavirus Vaccine ◽  
Specimen Collection ◽  
National Programs ◽  
Collection Date ◽  
Papillomavirus Vaccine ◽  
Prevalence Ratios

Abstract Background Highly effective human papillomavirus (HPV) vaccines are used in many national programs in 3- or 2-dose schedules. We examined HPV vaccine effectiveness against HPV prevalence by number of doses. Methods We collected residual liquid-based cytology samples from US women aged 20–29 years who were screened for cervical cancer. Women continuously enrolled from 2006 through the specimen collection date were analyzed. Specimens were tested using the Linear Array assay. We analyzed prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV 6,11,16,18) and other HPV-type categories and determined prevalence ratios (PRs) and 95% confidence intervals (CIs) for 1, 2, and 3 compared with no vaccine doses. Results Among 4269 women, 1052 (24.6%) were unvaccinated, 2610 (61.1%) received 3 doses, 304 (7.1%) received 2 doses, and 303 (7.1%) received 1 dose. The 4vHPV-type prevalence was 7.4% among unvaccinated women compared with 1.7%, 1.0%, and 1.0% among 1-, 2-, and 3-dose recipients. Among women vaccinated at ≤18 years, adjusted PRs for 1, 2, and 3 doses were 0.06 (95% CI, 0.01–0.42), 0.05 (95% CI, 0.01–0.39), and 0.06 (95% CI, 0.04–0.12). Conclusions Among women who received their first dose at age ≤18, estimated HPV vaccine effectiveness was high regardless of number of doses.

Human papillomavirus vaccine timing associated with eventual human papillomavirus diagnosis in women

2020 ◽  
Vol 31 (10) ◽  
pp. 976-981
Author(s):  
Robert J Zeglin ◽  
Juliet L Fetteroll
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Sexual Debut ◽  
Secondary Data ◽  
Hpv Infection ◽  
Nutrition Examination Survey ◽  
Human Papillomavirus Vaccine ◽  
Vaccination Rates ◽  
Health And Nutrition ◽  
Papillomavirus Vaccine

Nearly all cases of cervical cancer are attributable to human papillomavirus (HPV), making it a significant women’s health issue. Though there have been advances in the prevention of HPV via vaccination, significant barriers continue to suppress vaccination rates for girls. Delaying vaccination until after sexual debut increases a woman’s chance of HPV infection, but there has been no quantification of this risk in the literature. The present study sought to address this gap via secondary data analysis with 173 female participants from the 2015–2016 National Health and Nutrition Examination Survey dataset. Results indicate that women in the sample who received the HPV vaccine after their sexual debut were 2.63 times more likely than women who receive the vaccine before their sexual debut to report an HPV diagnosis. These results have clear public and sexual health implications.

Human papillomavirus vaccine series follow-through: comparison of four clinics in an academic medical center

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Abigail McRea ◽  
Brittney Moore ◽  
Hannah Morris ◽  
Lindsay Cortright ◽  
Cierra Buckman ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Family Medicine ◽  
Hpv Vaccine ◽  
Medical Center ◽  
Academic Medical Center ◽  
Multivariable Analysis ◽  
Vaccine Uptake ◽  
Adolescent Medicine ◽  
Human Papillomavirus Vaccine ◽  
Effective Strategies

AbstractObjectiveThe Centers for Disease Control & Prevention (CDC) recommends that the human papillomavirus (HPV) vaccine series be initiated at ages 11–12 years, but many children never follow-through with the series. By examining differences in clinic-specific vaccine series follow-through rates across four clinics, we aimed to identify best practices related to communication around the vaccine and pathways to follow-through.MethodsWe used the electronic medical record (EMR) to retrospectively analyze HPV vaccine follow-through at four clinic settings. We limited the sample to children ages 11–17 who received a dose of the vaccine series at any of the clinics between January 2015 and June 2018. The primary outcome was follow-through of the HPV vaccine series within 18 months of initiation.ResultsA total of 3,813 patients were included in this study, 29% of which followed through with the HPV vaccine series. There was significant variability of vaccine follow-through among the clinics (p<0.001), with the Med/Peds clinic having the highest rate of follow-through (32%). After adjusting for confounding variables, multivariable analysis found that Med/Peds and Family Medicine had higher odds of HPV vaccine series follow-through than the Pediatrics clinic.ConclusionsWe found that the likelihood of vaccine series follow-through was highest when the series was started in the Med/Peds and Family Medicine clinics, compared to Pediatrics and Adolescent Medicine. These results suggest that further qualitative research is needed to understand what communication strategies are most effective at facilitating HPV vaccine uptake among adolescents, and how the most effective strategies can be shared among clinics.

scholarly journals Parental Human Papillomavirus Vaccine Survey (PHPVS): Nurse-Led Instrument Development and Psychometric Testing for Use in Research and Primary Care Screening

2013 ◽  
Vol 21 (1) ◽  
pp. 96-109 ◽  
Author(s):  
Tami Lynn Thomas ◽  
Ora L. Strickland ◽  
Ralph DiClemente ◽  
Melinda Higgins ◽  
Bryan Williams ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Item Analysis ◽  
Health Belief ◽  
Psychometric Testing ◽  
Hpv Infection ◽  
Human Papillomavirus Vaccine ◽  
Hpv Knowledge ◽  
Belief Model ◽  
Papillomavirus Vaccine ◽  
Intent To Vaccinate

Background and Purpose: Human papillomavirus (HPV) vaccine was approved for girls aged 9–24 years in 2006 to prevent HPV infection and cervical cancer. The Parental Human Papillomavirus Survey (PHPVS) was framed on theoretical constructs of the health belief model (HBM) and developed to survey parents regarding their HPV knowledge, attitudes, and intent to vaccinate. Methods: We evaluated the psychometric properties of the PHPVS using classical item analysis and exploratory factor analysis (EFA) among a sample of 200 parents/caregivers. Results: The EFA yielded a 4-factor unidimensional model that explained between 62% and 68% of the total variance depending on the extraction method used. The estimated Cronbach’s alpha for the PHPVS was .96. Conclusions: The PHPVS is a reliable measure of HPV knowledge, attitudes, and intent to vaccinate.

scholarly journals Evaluation of a Perinatal Human Papillomavirus Program

2018 ◽  
Author(s):  
Melissa Maher
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Sexual Debut ◽  
The United States ◽  
Hpv Infection ◽  
Pilot Program ◽  
Postpartum Visit ◽  
Transmitted Infection ◽  
Advanced Nursing Practice ◽  
Vaccination Rates

Human papillomavirus (HPV) is recognized as the most prevalent sexually transmitted infection in the United States. Prevention of HPV infection is possible with the efficacy of HPV vaccine noted to be nearly 100% when introduced prior to sexual debut. In addition, vaccination post-sexual initiation could have a significant impact on reducing HPV infection and HPV-associated cancers in women. Much focus has been placed on vaccinating adolescents against HPV. However, strategies to increase vaccination rates among females ages 18-26, who remain eligible for vaccination, must be examined. A program evaluation was undertaken to assess the effectiveness of a newly developed pilot program for women ages 19-26 that incorporates assessment of vaccine eligibility during the prenatal period to increase uptake and completion of HPV vaccine postpartum. Data collected from the perinatal vaccination pilot program was performed retrospectively. Through a chart review, postpartum patients age 19-26 were identified and specific areas of focus were examined: whether an HPV dose was administered to vaccine eligible individuals during the inpatient period; whether an additional dose was administered at an ambulatory postpartum visit; and whether a subsequent dose was given at an ambulatory visit if warranted. Data analysis was conducted. Frequencies and percentages in relation to numbers of patients and HPV doses were calculated. Finally, implications for advanced nursing practice were discussed.

Sign in / Sign up

Export Citation Format

Share Document